{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > MAPK > RAF-265CAS：927880-90-8
Molecular Formula：C24H16F6N6O
Molecular Weight：518.41
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to brown Solid
Qty：
Size：
| CAS | 927880-90-8 |
| Name | RAF-265 |
| Molecular Formula | C24H16F6N6O |
| Molecular Weight | 518.41 |
| Solubility | Soluble in DMSO ≥5mg/mL |
| Purity | ≥98% |
| Appearance | White to brown Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD16659061 |
| SMILES | FC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F |
| Target Point | Raf |
| Passage | MAPK |
| Background | RAF265 is a potent RAF/VEGFR2 inhibitor. |
| Biological Activity | RAF265 是一种有效的 RAF/VEGFR2 抑制剂。[1] |
| Data Literature Source | [1]. Mordant P，et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265，a novel RAF/VEGFR2 inhibitor，and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9(2):358-68 |
| Unit | Bottle |
| Specification | 5mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
